Special Import - Mounjaro 15 mg Pen

Mounjaro Pen

Description:

Mounjaro pen (tirzepatide) is a prescription injectable medicine used for the management of type 2 diabetes mellitus and for medical weight management in adults. It is a once-weekly subcutaneous injection that acts as a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, helping improve blood sugar control and support clinically significant weight loss when combined with diet and exercise. This product belongs to the diabetes care and weight management segment and must be used under medical supervision.

Indications:

• Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
• As monotherapy when metformin is considered inappropriate due to intolerance or contraindications.
• In combination with other antidiabetic medicinal products for the treatment of type 2 diabetes mellitus (e.g., metformin, SGLT2 inhibitors, insulin) as prescribed by a physician.
• Weight management, including weight loss and weight maintenance, as an adjunct to a reduced-calorie diet and increased physical activity in adults with:
• Body Mass Index (BMI) ≥ 30 kg/m2 (obesity), or
• BMI ≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition such as hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, prediabetes, or type 2 diabetes mellitus.
• Helps reduce elevated blood glucose levels (fasting and postprandial) in adults with type 2 diabetes.

Active Ingredients / Key Components:

• Tirzepatide – 10 mg per 0.5 ml solution for injection (10 mg/0.5 ml).
• Each prefilled pen delivers 10 mg tirzepatide in 0.5 ml for subcutaneous use.
• Excipients: Detailed excipient list and concentrations , please check the product leaflet or the manufacturer’s official website; please refer to the official package leaflet for full composition.

Dosage & Administration / How to Use:

• Mounjaro is for subcutaneous injection only and must be used exactly as prescribed by a healthcare professional.
• Starting dose: 2.5 mg once weekly for 4 weeks.
• Dose escalation: After 4 weeks at 2.5 mg, increase to 5 mg once weekly. If additional glycaemic or weight control is needed, the dose may be increased in 2.5 mg increments (e.g., 7.5 mg, 10 mg, 12.5 mg, 15 mg) after a minimum of 4 weeks on the current dose, according to the prescriber’s instructions.
• Recommended maintenance doses: 5 mg, 10 mg, or 15 mg once weekly, as determined by the treating physician.
• Maximum dose: 15 mg once weekly.
• Route of administration: Subcutaneous injection in the abdomen, thigh, or upper arm.
• The injection can be administered at any time of the day, with or without food.
• Rotate injection sites with each dose to reduce the risk of lipodystrophy or skin irritation.
• If the patient is also using insulin, inject Mounjaro and insulin at different injection sites; do not mix them in the same syringe.
• If a dose is missed, follow the instructions provided by the prescribing doctor or the official leaflet (information on exact missed-dose window is not available here; consult the leaflet).
• Do not use the pen if it appears damaged, has been frozen, or if the solution is discolored or contains particles.

Clinical Benefits:

• Improves glycaemic control in adults with type 2 diabetes by enhancing insulin secretion and reducing glucagon levels in a glucose-dependent manner.
• Supports significant weight loss and long-term weight maintenance when combined with a reduced-calorie diet and increased physical activity.
• Helps reduce fasting and postprandial blood glucose, contributing to lower HbA1c levels.
• May reduce cardiometabolic risk factors associated with obesity and type 2 diabetes, such as high blood pressure, dyslipidaemia, and central adiposity (as part of an overall treatment plan).
• Once-weekly dosing improves treatment convenience and may enhance adherence compared to daily injections.

Warnings & Contraindications:

• Mounjaro (tirzepatide) is a prescription-only medicine and should be used strictly under the supervision of a qualified healthcare professional.
• Contraindicated in patients with known hypersensitivity to tirzepatide or any of the excipients.
• Not indicated for the treatment of type 1 diabetes mellitus or for diabetic ketoacidosis.
• Not a substitute for insulin in patients requiring insulin.
• Use with caution in patients with a history of pancreatitis; discontinue and seek medical attention if severe abdominal pain occurs.
• May cause gastrointestinal adverse reactions (nausea, vomiting, diarrhoea); dehydration can occur, especially in patients with renal impairment – maintain adequate fluid intake.
• Hypoglycaemia risk is increased when used with insulin or insulin secretagogues (e.g., sulfonylureas); dose adjustment of concomitant therapy may be required.
• Limited data in severe renal or hepatic impairment; use only if the potential benefit justifies the potential risk and under close monitoring.
• Thyroid-related warnings (e.g., risk of C-cell tumours) have been observed in GLP-1 receptor agonist class in animal studies; patients with personal or family history of medullary thyroid carcinoma or MEN2 should discuss risks with their doctor. Refer to the official leaflet for specific class warnings.
• Pregnancy and lactation: Safety data in pregnant or breastfeeding women are limited; use only if clearly needed and after medical evaluation. Effective contraception is recommended for women of childbearing potential while on therapy.
• May cause dizziness or fatigue in some patients; caution is advised when driving or operating machinery until the individual response is known.
• Consult your doctor before use if pregnant, nursing, taking other medications, or if you have medical conditions such as pancreatitis, severe gastrointestinal disease, kidney disease, liver disease, thyroid disorders, cardiovascular disease, or diabetic retinopathy.
• Keep out of reach of children.
• This product must not be used for any purpose other than that for which it is prescribed.

Side Effects:

• Common side effects: Nausea, vomiting, diarrhoea, decreased appetite, constipation, abdominal pain, dyspepsia, fatigue, injection site reactions (redness, itching, or mild swelling).
• Less common but potentially serious side effects: Pancreatitis (severe and persistent abdominal pain, possibly radiating to the back), severe gastrointestinal symptoms with dehydration, gallbladder problems (e.g., cholelithiasis, cholecystitis), possible allergic reactions (rash, itching, swelling, difficulty breathing).
• Hypoglycaemia: Especially when used with insulin or sulfonylureas; symptoms include sweating, tremor, palpitations, hunger, confusion, or dizziness. Seek medical attention if severe or recurrent.
• Discontinue use and seek immediate medical help if you experience signs of a serious allergic reaction (anaphylaxis) or severe abdominal pain suggestive of pancreatitis.
• This is not a complete list of side effects. For full safety information, consult the official patient leaflet or your healthcare provider.

Storage Instructions:

Store in a refrigerator at 2–8 °c unless otherwise specified on the pack. Do not freeze. Protect from direct sunlight and excessive heat. Keep the pen in the original carton to protect it from light. Once removed from the refrigerator, follow the in-pack instructions for in-use storage conditions and shelf life. Keep container tightly closed (if applicable) and keep out of reach of children.

Specifications:

• Active ingredient: tirzepatide 10 mg per 0.5 ml solution for injection.
• Form: Prefilled subcutaneous injection pen (solution for injection).
• Route: Subcutaneous use only (abdomen, thigh, or upper arm).
• Strength: 10 mg/0.5 ml.
• Pack information: The original note references “mounjaro 10mg/0.5ml 4 s.c. vial”; the exact number of pens per pack for this specific presentation is not clearly stated in the provided information. Please refer to the outer carton for exact pack size.
• Intended users: Adults with type 2 diabetes and/or obesity/overweight with weight-related comorbidities, as prescribed by a physician.

Disclaimer:
All pharmacy products are intended for general use only and do not replace professional medical advice, diagnosis, or treatment. Always consult a healthcare provider before use. Results may vary, and no specific outcomes are guaranteed. Products are not intended to diagnose, treat, cure, or prevent any disease unless stated. Follow label instructions carefully, as misuse may cause adverse effects. Compliance with local laws is the customer’s responsibility.